Pierre Payoux1, Anne Sophie Salabert. 1. aToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS bNuclear Medicine Department cRadiopharmacy Department, University Hospital of Toulouse, Toulouse, France.
Abstract
PURPOSE OF REVIEW: To present the new PET markers that could become in the coming years, relevant to advanced clinical approaches to dementia diagnosis, drug trials, and treatment strategies and discuss their advantages and limitations. RECENT FINDINGS: The most advanced new PET tracers are the markers of the amyloid plaques, the τ compounds and the tracers of the translocator protein as markers of neuroinflammation. The main advantages but also the weaknesses of each of these markers are discussed. The main pitfall remains the heterogeneity of the available results that cast doubt to a rapid introduction of these new ligands in clinical practice. SUMMARY: With the advent of biomarkers in clinical management and findings of molecular neuroimaging studies in the evaluation of patients with suspected dementia, the impact of functional neuroimaging has increased considerably these last years and has been integrated into many clinical guidelines in the field of dementia. In addition to conventional single PET brain perfusion and dopaminergic neurotransmission, 18F-fluorodeoxyglucose (18F-FDG) PET is used in advanced diagnosis procedures. Furthermore, new tracers are being developed to quantify key neuropathological features in the brain tissue as highly specific diagnosis is crucial to comply with the global medical and public health objectives in this domain. A strategic road map for further developments, adapted from the approach to cancer biomarkers, should be proposed so as to optimize the rationale of the PET-based molecular diagnosis of Alzheimer's disease and related disorders.
PURPOSE OF REVIEW: To present the new PET markers that could become in the coming years, relevant to advanced clinical approaches to dementia diagnosis, drug trials, and treatment strategies and discuss their advantages and limitations. RECENT FINDINGS: The most advanced new PET tracers are the markers of the amyloid plaques, the τ compounds and the tracers of the translocator protein as markers of neuroinflammation. The main advantages but also the weaknesses of each of these markers are discussed. The main pitfall remains the heterogeneity of the available results that cast doubt to a rapid introduction of these new ligands in clinical practice. SUMMARY: With the advent of biomarkers in clinical management and findings of molecular neuroimaging studies in the evaluation of patients with suspected dementia, the impact of functional neuroimaging has increased considerably these last years and has been integrated into many clinical guidelines in the field of dementia. In addition to conventional single PET brain perfusion and dopaminergic neurotransmission, 18F-fluorodeoxyglucose (18F-FDG) PET is used in advanced diagnosis procedures. Furthermore, new tracers are being developed to quantify key neuropathological features in the brain tissue as highly specific diagnosis is crucial to comply with the global medical and public health objectives in this domain. A strategic road map for further developments, adapted from the approach to cancer biomarkers, should be proposed so as to optimize the rationale of the PET-based molecular diagnosis of Alzheimer's disease and related disorders.
Authors: Anna M Pietroboni; Tiziana Carandini; Annalisa Colombi; Matteo Mercurio; Laura Ghezzi; Giovanni Giulietti; Marta Scarioni; Andrea Arighi; Chiara Fenoglio; Milena A De Riz; Giorgio G Fumagalli; Paola Basilico; Maria Serpente; Marco Bozzali; Elio Scarpini; Daniela Galimberti; Giorgio Marotta Journal: Eur J Nucl Med Mol Imaging Date: 2018-10-21 Impact factor: 9.236
Authors: Tammaryn Lashley; Jonathan M Schott; Philip Weston; Christina E Murray; Henny Wellington; Ashvini Keshavan; Sandrine C Foti; Martha Foiani; Jamie Toombs; Jonathan D Rohrer; Amanda Heslegrave; Henrik Zetterberg Journal: Dis Model Mech Date: 2018-05-08 Impact factor: 5.758
Authors: Lakshmi Narasimhan Ranganathan; R Guhan; M M Arun Shivaraman; P Lenin Sankar; A V Srinivasan; G Suriyakumar; A L Periakaruppan Journal: Ann Indian Acad Neurol Date: 2018 Apr-Jun Impact factor: 1.383